Purnima Rawat1, Kapil Manglani2, Sarika Gupta2, Abul Kalam3, Divya Vohora3, Farhan Jalees Ahmad1, Sushama Talegaonkar4. 1. Nanomedicine Research Lab, Department of Pharmaceutics Faculty of Pharmacy, Jamia Hamdard, New Delhi, 110062, India. 2. Molecular Sciences Lab, National Institute of Immunology, New Delhi, New Delhi, 110067, India. 3. Department of Pharmacology, Faculty of Pharmacy, Jamia Hamdard, New Delhi, 110062, India. 4. Nanomedicine Research Lab, Department of Pharmaceutics Faculty of Pharmacy, Jamia Hamdard, New Delhi, 110062, India. stalegaonkar@gmail.com.
Abstract
PURPOSE: Bioceramic(Hydroxyapatite) based Poly(D,L-lactide-co-glycolide) (PLGA) and polyethylene glycol (PEG) nanoparticles of Risedronate was prepared by dialysis method for bone-targeting. METHODS: Risedronate, a targeting moiety that has a strong affinity for bone, was conjugated to PLGA via carbodiimide chemistry. Mono-methoxy PEG(mPEG)-PLGA block polymers were synthesized and used to impart surface hydrophilicity to nanoparticles to avoid its uptake by reticuloendothelial system (RES). The structure of prepared di block copolymers were characterized by FT-IR and NMR spectrometry. Risedronate was adsorbed on the surface of hydroxyapatite (RIS-HA) and it was conjugated with different ratios of mPEG-PLGA. The formation of surface-modified PLGA nanoparticle prepared with various ratios of risedronate as well as hydroxyapatite and mPEG was confirmed by (1)H NMR and FT-IR spectrometry. RESULTS: Size and % entrapment of the prepared nanoparticle was found to be 79.3 ± 2.3 nm and 93 ± 3.1%. Transmission electron microscopy (TEM) revealed that mPEG-PLGA-RIS-HA nanoparticles possess smooth and uniform surface. Pharmacodynamic study was performed on Dexamethasone (DEX) induced osteoporotic model. The effect of various formulations (mPEG-PLGA-RIS, mPEG-PLGA-RIS-HA and RISOFOS tablet) on bone was studied by Volume bone density (VBD) and by histopathological evaluation. Interestingly mPEG-PLGA-RIS-HA, showed a significant enhancement in bone micro-architecture when compared with other formulations. CONCLUSIONS: The results strongly implicated that mPEG-PLGA-RIS-HA has a therapeutic benefits over risedronate sodium monotherapy for the treatment of osteoporosis in a rat model.
PURPOSE: Bioceramic(Hydroxyapatite) based Poly(D,L-lactide-co-glycolide) (PLGA) and polyethylene glycol (PEG) nanoparticles of Risedronate was prepared by dialysis method for bone-targeting. METHODS:Risedronate, a targeting moiety that has a strong affinity for bone, was conjugated to PLGA via carbodiimide chemistry. Mono-methoxy PEG(mPEG)-PLGA block polymers were synthesized and used to impart surface hydrophilicity to nanoparticles to avoid its uptake by reticuloendothelial system (RES). The structure of prepared di block copolymers were characterized by FT-IR and NMR spectrometry. Risedronate was adsorbed on the surface of hydroxyapatite (RIS-HA) and it was conjugated with different ratios of mPEG-PLGA. The formation of surface-modified PLGA nanoparticle prepared with various ratios of risedronate as well as hydroxyapatite and mPEG was confirmed by (1)H NMR and FT-IR spectrometry. RESULTS: Size and % entrapment of the prepared nanoparticle was found to be 79.3 ± 2.3 nm and 93 ± 3.1%. Transmission electron microscopy (TEM) revealed that mPEG-PLGA-RIS-HA nanoparticles possess smooth and uniform surface. Pharmacodynamic study was performed on Dexamethasone (DEX) induced osteoporotic model. The effect of various formulations (mPEG-PLGA-RIS, mPEG-PLGA-RIS-HA and RISOFOS tablet) on bone was studied by Volume bone density (VBD) and by histopathological evaluation. Interestingly mPEG-PLGA-RIS-HA, showed a significant enhancement in bone micro-architecture when compared with other formulations. CONCLUSIONS: The results strongly implicated that mPEG-PLGA-RIS-HA has a therapeutic benefits over risedronate sodium monotherapy for the treatment of osteoporosis in a rat model.
Entities:
Keywords:
bioceramic; bone density; nanoparticle; osteoporosis; risedronate
Authors: A Ezra; A Hoffman; E Breuer; I S Alferiev; J Mönkkönen; N El Hanany-Rozen; G Weiss; D Stepensky; I Gati; H Cohen; S Törmälehto; G L Amidon; G Golomb Journal: J Med Chem Date: 2000-10-05 Impact factor: 7.446
Authors: Sydney Bonnick; Kenneth G Saag; Douglas P Kiel; Michael McClung; Marc Hochberg; Sherri-Ann M Burnett; Anthony Sebba; Risa Kagan; Erluo Chen; Desmond E Thompson; Anne E de Papp Journal: J Clin Endocrinol Metab Date: 2006-04-24 Impact factor: 5.958
Authors: H Murakami; N Takahashi; T Sasaki; N Udagawa; S Tanaka; I Nakamura; D Zhang; A Barbier; T Suda Journal: Bone Date: 1995-08 Impact factor: 4.398
Authors: Diêgo Dos Santos Ferreira; Samilla Dornelas Faria; Sávia Caldeira de Araújo Lopes; Cláudia Salviano Teixeira; Angelo Malachias; Rogério Magalhães-Paniago; José Dias de Souza Filho; Bruno Luis de Jesus Pinto Oliveira; Alexander Ramos Guimarães; Peter Caravan; Lucas Antônio Miranda Ferreira; Ricardo José Alves; Mônica Cristina Oliveira Journal: Int J Nanomedicine Date: 2016-08-09